ASX
LCT 0.057    Last updated 4.30 pm
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 

LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

 

The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson’s disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease-modifying treatment for patients with Parkinson’s disease. It has the potential to be used in a number of other central nervous system indications such as Huntington’s, Alzheimer’s and motor neurone diseases.

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system. 

 

LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

 

— 3 February 2016

LCT receives ethics approval for Phase IIb Parkinson’s trial

Living Cell Technologies has received approval from the Northern A Health and Disability Ethics Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. The New Zealand Minister of Health authorised the application to conduct the trial on 12 November 2015.

Read More Read Less

— 27 January 2016

NTCELL reverses the progression of Parkinsons disease - one year after implant

Over a year after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well, and at 58 weeks post-implant there are no safety concerns.

Read More Read Less
Load More

— 8 May 2014

Please refer to our news releases

Load More

There are no forthcoming events at present.

Load More
Announcements

— 3 February 2016

LCT receives ethics approval for Phase IIb Parkinson’s trial

Living Cell Technologies has received approval from the Northern A Health and Disability Ethics Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. The New Zealand Minister of Health authorised the application to conduct the trial on 12 November 2015.

Read More Read Less

— 27 January 2016

NTCELL reverses the progression of Parkinsons disease - one year after implant

Over a year after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well, and at 58 weeks post-implant there are no safety concerns.

Read More Read Less
Load More
LCT in the News

— 8 May 2014

Please refer to our news releases

Load More
Events

There are no forthcoming events at present.

Load More
© 2016 Living Cell Technologies Limited.
site by { brownpaperbag }